biotech / news / / Benzinga
Moderna Revenue Beats Despite Litigation Impact.
Moderna's adjusted Q1 loss was $1.18 per share, far narrower than expected $3.81 loss.
KEY POINTS
- Revenue reached $389 million, significantly exceeding the consensus estimate of $227.97 million.
- International COVID vaccine sales increased due to long-term partnerships with government entities.
- Moderna began Phase 3 trials for its mRNA H5 pandemic flu vaccine candidate, mRNA-1018.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →